• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600085.SS
Share

Beijing Tongrentang Co., Ltd Stocks

CN¥ 24.87Last Updated 26.10.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 5.07B

CN¥ 24.87
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Somewhat favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beijing Tongrentang Co., Ltd engages in the production and sale of traditional Chinese medicine preparations in China and internationally. The company offers various product dosage forms, such as pills, powders, medicated wines, capsules, oral liquids, and drop pills. Its products are used for cardiovascular, cerebrovascular, gynecology, heat-clearing, respiratory system, nourishing and calming, digestive, pediatrics, wind-dispelling and dampness removing, orthopedics, facial features, dermatological surgery, mental health, and food and beverages applications. The company was founded in 1997 and is based in Beijing, China. Beijing Tongrentang Co., Ltd operates as a subsidiary of China Beijing Tong Ren Tang Group Co. Ltd.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 600085.SS is 32.4 and suggests 31.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 01:51

Anthropic Disclosed Its Reliance on Google, Amazon, and Microsoft Ahead of Its IPO. What Is the Risk?

27.10.2026 00:38

Microsoft is cutting costs: 60,000 employees have been offered voluntary separation

27.10.2026 00:18

"If the bubble bursts, it will all start with debt": How the problems of the neo-claws threaten the S&P 500

26.10.2026 23:40

Buyers of the foldable iPhone have complained about screen damage. How does this affect the stock price?

26.10.2026 23:02

One of Wall Street’s biggest bulls drops overweight call on stocks ahead of midterms

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026